Clinical Trial Update: Epoetin Alfa for HIV-Associated Neuropathy Trial [Phase 2]

View source ↗

Summary

The Phase 2 trial of epoetin alfa for HIV-associated neuropathy has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Peripheral Neuropathy

Drugs mentioned

• Epogen (epoetin alfa)
• PROCRIT (ERYTHROPOIETIN)

Snippet

Sponsor: Washington University School of Medicine | Conditions: HIV Infections, Neuropathy | Phase 2 | Status: WITHDRAWN